ABBV vs LLY
AbbVie and Eli Lilly, both Healthcare
Eli Lilly is the larger company at $1.2T against $505B. On trailing earnings LLY is the cheaper of the two at a P/E of 42.8 against 80.7, a gap that is only a bargain if the two are growing at similar rates. Over the past year LLY returned +56% against +28% for ABBV. The RyuScore puts LLY ahead, 60 against 48 out of 100.
| Figure | ABBV | LLY |
|---|---|---|
| Last close | $286 | $1274 |
| Market cap | $505B | $1.2T |
| Trailing P/Elower is cheaper for the same earnings, not automatically better | 80.7 | 42.8 |
| Dividend yield | 2.3% | 0.5% |
| 1-year return | +28% | +56% |
| 5-year return | +209% | +470% |
| RyuScoresector-relative, 1–10 | 48/100 | 60/100 |
Figures from SEC filings and end-of-day closes. Highlighting marks the higher or lower number, which is not the same as the better investment, a low P/E can be a warning and a high one can be deserved.
AbbVie
Revenue of $17B in Q2 2026, net income $3.6B. Its largest reported line is SKYRIZI, 36% of the disclosed total.
Eli Lilly
Revenue of $23B in Q2 2026, net income $7.1B. Its largest reported line is Cardiometabolic Health, 47% of the disclosed total.
Open these two in the interactive comparison to add more names, change the period or see the correlation.